Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$10.61 USD
+0.09 (0.86%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.67 +0.06 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CDTX 10.61 +0.09(0.86%)
Will CDTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Other News for CDTX
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
Cidara Therapeutics announces new appointment to its Scientific Advisory Board